|
|
William Cook's Cholesterol Plunges on Tower Heart Technology Formula
|
Added: 02/07/2004
Type: Summary
Viewed: 910 time(s)
[ Not Rated Yet ] |
William Cook's Cholesterol Plunges on Tower Heart Technology Formula
All statins - natural or artificial - lower cholesterol by blocking the same essential enzyme. In 1985 Harwood, et. al., made the important discovery that ascorbic acid (Vitamin C) is the human body's natural HMG-CoA reductase inhibitor, without the liver-destroying potential. When vitamin C levels are low, the body compensates and manufactures more cholesterol; when vitamin levels are high, vitamin C inhibits HMG-CoA reductase, predictably lowering cholesterol.
Cook, declined the artificial statin in mid-April of 2002 following emergency triple bypass surgery. Instead, he began Tower Heart Technology after watching a video of Nobelist Linus Pauling explaining the value of vitamin C for cardiovascular disease. William had his first heart attack on March 17, 2002 and a second 10 days later on March 27, 2002. In December of 2001 prior to his heart attacks, Bill's numbers had been Cholesterol 242 and LDL Cholesterol 163.
Cook and long-time friend Sally Jewell had both worried about their decision, but they became jubilant after the blood tests results came in, " To our wonderment and surprise, in 8 months his cholesterol had dropped from 246 to 164 and his LDL cholesterol had dropped from 163 to 101, all on 2 jars of Tower Heart Technology per month, plus 2,000 mg. additional vitamin C as ascorbic acid."
When the lab report was examined, William's doctor said, "I've never seen such a drop in cholesterol numbers. If cardiologists knew this, they would be recommending vitamin C and lysine therapy to all their patients."
There are several known problems with artificial statin drugs, such as the popular LipitorŅ or ZocorŅ, which have prompted an investigation by the National Institutes of Health. These drugs may harm the liver and increase several cardiovascular risk factors; they reduce circulating levels of ubiquinone, also know as coenzyme Q10 (CoQ10) and they raise levels of Lp(a) cholesterol.
The declines in CoQ10 -- attributed to artificial statins -- have been linked to muscle pain, muscle myopathy and congestive heart failure. In 2000, researchers at Oxford University linked elevated Lp(a) to the 70 percent higher probability of heart attack or stroke. Warnings to these effects are carried by Canadian, but not U.S. statin drug advertisements.
It is known that Vitamin C is required for the body to synthesize CoQ10, and the vitamin has been shown to decrease circulating levels of Lp(a). Vitamin C, a primary antioxidant, also protects the liver.
William Cooks before and after lab reports have been scanned and placed on the Internet. Visit
http://www.internetwks.com/billcook
Harwoods paper is:
Inhibition of HMG-CoA reductase activity by ascorbic acid
HJ Harwood Jr, YJ Greene and PW Stacpoole
J. Biol. Chem., Vol. 261, Issue 16, 7127-7135, 06, 1986
On the Internet visit:
http://www.jbc.org/cgi/content/abstract/261/16/7127
Information about the Linus Pauling video on Heart Disease is available at:
http://www.PaulingTherapy.com
Heart Technology is manufactured in the United States of America by Tower Laboratories Corporation, Las Vegas, Nevada. Tower Laboratories is an industry leader in the manufacture and distribution of several popular supplements and high-antioxidant nutritional drink mixes for sustaining cardiovascular health.
Visit http://www.HeartTechnology.com to learn more.
CONTACTS:
Sally Jewell, P.O.
Box 21755 Louisville,
KY 40221-0755
(502) 368-2720
Fax: (502) 368-2721
sally@hearttechnologykentucky.com
Owen R. Fonorow,
P O Box 3097
Lisle, IL 60532
800-894-9025
Fax: (630) 416-1309 |
Article Pages: 1
Article Comments
 Add Comment |
 View All (0)
There are currently no comments for this article.
|
|
|
Good Resources